A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine infusion in individuals with PTSD showed significant and rapid PTSD symptom reduction 24 hours postinfusion. The present study is the first randomized controlled trial to test the efficacy and safety of repeated intravenous ketamine infusions for the treatment of chronic PTSD. METHODS: Individuals with chronic PTSD (N=30) were randomly assigned (1:1) to receive six infusions of ketamine (0.5 mg/kg) or midazolam (0.045 mg/kg) (psychoactive placebo control) over 2 consecutive weeks. Clinician-rated and self-report assessments were administered 24 hours after the first infusion and at weekly visits. The primary outcome measure was change in PTSD symptom severity, as assessed with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), from baseline to 2 weeks (after completion of all infusions). Secondary outcome measures included the Impact of Event Scale-Revised, the Montgomery-Åsberg Depression Rating Scale (MADRS), and side effect measures. RESULTS: The ketamine group showed a significantly greater improvement in CAPS-5 and MADRS total scores than the midazolam group from baseline to week 2. At week 2, the mean CAPS-5 total score was 11.88 points (SE=3.96) lower in the ketamine group than in the midazolam group (d=1.13, 95% CI=0.36, 1.91). Sixty-seven percent of participants in the ketamine group were treatment responders, compared with 20% in the midazolam group. Among ketamine responders, the median time to loss of response was 27.5 days following the 2-week course of infusions. Ketamine infusions were well tolerated overall, without serious adverse events. CONCLUSIONS: This randomized controlled trial provides the first evidence of efficacy of repeated ketamine infusions in reducing symptom severity in individuals with chronic PTSD. Further studies are warranted to understand ketamine's full potential as a treatment for chronic PTSD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another study of repeat-dose ketamine (six infusions over two weeks, n = 30) found a response rate of 67% [102]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [102]
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 2×
“…were assessed before infusion and at 40 and 120 minutes after start of infusion with the Clinician-Administered Dissociative States Scale (28), the 4-item positive symptom subscale of the Brief Psychiatric Rating Scale (29), and the fi rst item (elevated mood) of the Young Mania Rating Scale (30).”
MethodPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“…a rapid increase in glutamate release, triggering several downstream signaling pathways (including brain-derived neurotrophic factor [BDNF] and mammalian target of rapamycin complex 1 [mTORC1]), resulting in increased synaptogenesis and synaptic spine maturation in key brain regions (33, 34).”
BackgroundAssessing psychological trauma and PTSD
(1997) · Choice Reviews Online · doi:10.5860/choice.34-5966 · Cited by 2,330
Weathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., Keane, T. M., & Marx, B. P. (2018) · Psychological Assessment · doi:10.1037/pas0000486 · Cited by 1,799 · cited 15×
“The study involved three phases: 1) screening, during which participants were assessed for eligibility and any required medication tapering took place; 2) a 2-week treatment phase, during which participants received six in-fusionsofstudydrugapproximatelythreetimesperweekand were assessed on each infusion day, as well…”
MethodInfluentialTrauma and PTSD in the WHO World Mental Health Surveys
Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Benjet, C., Bromet, E. J., Cardoso, G., Degenhardt, L., de Girolamo, G., Dinolova, R. V., Ferry, F., et al. (2017) · European Journal of Psychotraumatology · doi:10.1080/20008198.2017.1353383 · Cited by 1,661 · cited 1×
“Rates vary by trauma type, severity, and cumulative trauma exposure, with the highest PTSD burden among survivors of interpersonal violence (2).”
BackgroundKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 1×
“…to develop novel pharmacologic interventions for chronic PTSD. Ketamine, fi rstapprovedbytheFDAasananestheticagent in 1970 (11), is a noncompetitive glutamate N -methyl- D -as- partate (NMDA) receptor antagonist, with lower af fi nity for serotonin, dopamine, opioid, and other receptors (12).”
Background
Research works printed but not linked: 2
- Golier JA, 2012, Depress Res Treat, 2012, 393251
- First MB, 2015, Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV)
Cited by
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“The primary endpoint was defined as change from baseline to two weeks in PTSD symptom severity, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5).”
BackgroundInfluentialKohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
“Most recently, the first randomized controlled trial of repeated ketamine in PTSD found ketamine to elicit better improvement than the active control group receiving midazolam [75].”
BackgroundNovel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“In addition to these robust antidepressant effects, a single subanesthetic-dose (R,S)-ketamine infusion has also been found to have significant and rapid (1–4 h) anti-suicidal ideation effects [48–53], anti-anhedonic properties [54, 55], and therapeutic potential in other disorders such as posttraumatic stress disorde…”
BackgroundJowf, G. I. A., Ahmed, Z. T., Reijnders, R. A., de Nijs, L., & Eijssen, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065238 · Cited by 167
Abdallah, C. G., Roache, J. D., Gueorguieva, R., Averill, L. A., Young-McCaughan, S., Shiroma, P. R., Purohit, P., Brundige, A., Murff, W., Ahn, K.-H., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01266-9 · Cited by 111
“However, consistent with a recent report [11], the study treatment regimen was found to be well tolerated, showing significant reductions in the dissociative and psychotomimetic symptoms over the treatment period.”
BackgroundMethodResultInfluentialThe antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 108
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“Another study of repeat-dose ketamine (six infusions over two weeks, n = 30) found a response rate of 67% [102].”
BackgroundInfluentialPharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub4 · Cited by 98
Arketamine, a new rapid-acting antidepressant: A historical review and future directions
Zhang, J.-C., Yao, W., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109219 · Cited by 99
Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
“Although previous studies suggest that response to a single, first infusion of ketamine is a fairly robust predictor of response to subsequent, serial infusions [45], some [46, 47] (but not all [48]) findings suggest enhanced outcomes can be achieved even among first infusion non-responders through sustained treatment.”
ResultSelf-citationThe Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Pharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T., Phillips, N. J., Stein, D. J., & Ipser, J. C. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub3 · Cited by 73
Miller, A. H., & Raison, C. L. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01887-y · Cited by 67
“The seduction of serendipity; the reification of diagnostic nomenclature and the notion that “one size fits all” Early identification of pharmacologic therapies for psychiatric diseases was the result of serendipitous observations regarding the efficacy of drugs like thioridazine and impramine, which were Class of med…”
BackgroundKetamine and psychotherapy for the treatment of psychiatric disorders: Systematic review
Kew, B. M., Porter, R. J., Douglas, K. M., Glue, P., Mentzel, C. L., & Beaglehole, B. (2023) · BJPsych Open · doi:10.1192/bjo.2023.53 · Cited by 69
Long term structural and functional neural changes following a single infusion of Ketamine in PTSD
Duek, O. A., Korem, N., Li, Y., Kelmendi, B., Amen, S. L., Gordon, C., Milne, M., Krystal, J. H., Levy, I., & Harpaz‐Rotem, I. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01606-3 · Cited by 82
“The use of midazolam in such studies and reasoning was reported and discussed in previous published work [37, 44].”
BackgroundMethodInfluentialSingewald, N., Sartori, S. B., Reif, A., & Holmes, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109418 · Cited by 67
Neurobiology and Treatment of Posttraumatic Stress Disorder
Shalev, A. Y., Cho, D., & Marmar, C. R. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240536 · Cited by 82
Lv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211056743 · Cited by 56
Psilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Ragnhildstveit, A., Roscoe, J., Bass, L. C., Averill, C. L., Abdallah, C. G., & Averill, L. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231154125 · Cited by 56
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Mitchell, J., & Anderson, B. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01656-7 · Cited by 57
“…trial demonstrated that 2 weeks of 3× weekly ketamine infusions are ef fi cacious for up to a month in those with severe PTSD [98], a larger trial found no signi fi cant effect of 4 weeks of 2× weekly ketamine infusions in a population of military Veterans and service members…”
BackgroundPsychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 55
Norbury, A., Rutter, S., Collins, A. B., Costi, S., Jha, M. K., Horn, S. R. G.-V., Kautz, M. M., Corniquel, M. B., Collins, K. A., Glasgow, A. M., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01104-4 · Cited by 48
Self-citationSwainson, J., Klassen, L. J., Brennan, S., Chokka, P. R., Katzman, M. A., Tanguay, R. L., & Khullar, A. (2022) · CNS Drugs · doi:10.1007/s40263-022-00897-2 · Cited by 54
MacKay, M., Yang, B. H., Dursun, S. M., & Baker, G. B. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230222092029 · Cited by 56
“D-Cycloserine and propranolol have been specifically used to target the fear circuitry associated with PTSD [140, 141], and synaptic-based strategies such as ketamine administration have also been tried [142].”
BackgroundThe Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis
Du, R., Han, R., Niu, K., Xu, J., Zhao, Z., Lu, G., & Shang, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.813103 · Cited by 56
“Patients in 4 studies (Table 1) (25, 26, 30, 35) received the Impact of Event Scale-Revised (IES-R) (51).”
BackgroundMethodInfluentialBajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43
Ma, L., Wang, L., Chang, L., Shan, J., Qu, Y., Wang, X., Wan, X., Fujita, Y., & Hashimoto, K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02192-6 · Cited by 45
The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease
Mohammad Shehata, I., Masood, W., Nemr, N., Anderson, A., Bhusal, K., Edinoff, A. N., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022) · Neurology International · doi:10.3390/neurolint14020025 · Cited by 41
“The authors found that 70% of individuals responded with significant improvement in their symptoms during this period as measured by their clinician-administered PTSD Scale for the DSM-5 from baseline [45].”
MethodKnowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia
Glynos, N. G., Pierce, J. M., Davis, A. K., McAfee, J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.2022817 · Cited by 46
“2020) and clinical trials (Feder et al. 2021; Mitchell et al. 2021; Mithoefer et al. 2018) (see Krediet et al.”
BackgroundKetamine for post-traumatic stress disorders and it's possible therapeutic mechanism
Asim, M., Wang, B., Hao, B., & Wang, X. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105044 · Cited by 37
Toward staging differentiation for posttraumatic stress disorder treatment
Nijdam, M. J., Vermetten, E. H. G. J. M., & McFARLANE, A. C. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13520 · Cited by 46
Paredes-Echeverri, S., Guthrie, A. J., & Perez, D. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1040911 · Cited by 51
“, testing the potential utility of ketamine infusions) (59, 60).”
BackgroundA pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg, S. K., Choi, E. Y., Shapiro-Thompson, R., Dhaliwal, K., Neustadter, E. S., Sakheim, M., Null, K. E., Diaz, D. T., Rondeau, J. A., Pittaro, G. F., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01540-4 · Cited by 45
“Also, these results are similar to those from some studies in populations beyond TRD such as PTSD and OCD where ketamine was found to have transdiagnostic efficacy to reduce depressive and suicidal symptoms, but was less effective for disorder-specific symptoms [9, 10] (though data are mixed, and some studies have fou…”
ResultKetamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination
Halstead, M., Reed, S., Krause, R., & Williams, M. T. (2021) · Clinical Case Studies · doi:10.1177/1534650121990894 · Cited by 42
“New research suggests that ketamine also has benefit for the treatment of PTSD (Feder et al., 2014, 2021), although, there are fewer studies that examine ketamine-assisted psychotherapy (KAP) for this condition (Liriano et al., 2019).”
BackgroundArtin, H., Bentley, S., Mehaffey, E., Liu, F. X., Sojourner, K., Bismark, A. W., Printz, D., Lee, E., Martis, B., Peralta, S. D., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101439 · Cited by 41
Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder
Geldenhuys, C., van den Heuvel, L. L., Steyn, P., & Seedat, S. (2022) · CNS Drugs · doi:10.1007/s40263-022-00929-x · Cited by 39
“A follow-up RCT (n = 30) showed significant efficacy with repeated ketamine infusions over 2 weeks, with 67% of patients showing improvement in overall PTSD-symptoms on the CAPS-5, and clear superiority over placebo (midazolam) [108].”
BackgroundMoaddel, R., Zanos, P., Farmer, C., Kadriu, B., Morris, P. J., Lovett, J., Acevedo-Diaz, E. E., Cavanaugh, G. W., Yuan, P., Yavi, M., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01941-x · Cited by 32
“Ketamine also appears to effectively treat neuropathic pain [5], complex regional pain syndrome [6, 7], pre-and post-operative pain [8], and post-traumatic stress disorder (PTSD) [9, 10], in addition to having analgesic [11] and anti-inflammatory effects [8, 12].”
BackgroundLi, M., Yang, X., Yang, J., Li, T., Cui, C., Peng, X., Lei, J., Ren, K., Ming, J., Zhang, P., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.06.026 · Cited by 36
Rothärmel, M., Benosman, C., El‐Hage, W., Berjamin, C., Ribayrol, D., Guillin, O., Gaillard, R., Berkovitch, L., & Moulier, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.865466 · Cited by 40
Valenza, M., Facchinetti, R., Torazza, C., Ciarla, C., Bronzuoli, M. R., Balbi, M., Bonanno, G., Popoli, M., Steardo, L., Milanese, M., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02928-6 · Cited by 36
“Indeed, ketamine has been suggested as an effective treatment for PTSD and it should be further investigated [34, 96, 97], as clinical trials have reported a reduction in symptom severity in PTSD patients treated with this drug at subanesthetic doses [37, 98-100].”
Jumaili, W. A., Trivedi, C., Chao, T., Kubosumi, A., & Jain, S. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113804 · Cited by 29
Murray, S. L., & Holton, K. F. (2021) · Appetite · doi:10.1016/j.appet.2021.105599 · Cited by 32
Davis, L. L., & Hamner, M. B. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1356563 · Cited by 47
“…with chronic PTSD demonstrated that ketamine, an antagonist of the glutamate N-methyl-D-aspartate receptor, administered intravenously as either single or six repeated infusions over a 2-week period, resulted in clinically/signi fi cant improvements in PTSD symptoms compared with midazolam (98, 99).”
Sicignano, D. J., Kurschner, R., Weisman, N., Sedensky, A., Hernández, A. V., & White, C. M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231199666 · Cited by 31
“15,19,20 When we pooled the day 1 adverse event data from Feder 2014 with the last infusion day data from Feder 2021 (during 6th dose) and Abdallah 2022 (during 16th dose), only dry mouth (n = 2, OR 5.85 [95% CI 1.32 to 25.95]), dizziness (n = 2, OR 3.83 [95% CI 1.28 to 11.41]), and blurred vision…”
BackgroundMethodInfluentialKetamine as a prophylactic resilience-enhancing agent
Evers, A. G., Murrough, J. W., Charney, D. S., & Costi, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.833259 · Cited by 31
“Ketamine as a prophylactic resilience-enhancing agent Audrey G. Evers1, James W. Murrough1,2, Dennis S. Charney1,2,3 and Sara Costi1,4,5* 1Depression and Anxiety Center for Discovery and Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 2Department of Neuroscien…”
BackgroundInfluentialSelf-citationTrauma, Resilience, Anxiety Disorders, and PTSD
Kalin, N. H. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20121738 · Cited by 30
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 30
The diverse effects of ketamine, jack-of-all-trades: a narrative review
Richards, N. D., Howell, S. J., Bellamy, M. C., & Beck, J. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.11.018 · Cited by 33
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects
Hartland, H., Mahdavi, K., Jelen, L. A., Strawbridge, R., Young, A. H., & Alexander, L. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231161627 · Cited by 32
“Feder et al. (2021) (n = 30) used scores from the ClinicianAdministered PTSD Scale for DSM-5 (CAPS-5; Weathers et al., 2018) to assess symptom severity 1 week into treatment with multiple doses of intravenous ketamine (measured after fourth infusion) and at the end of treatment at 2 weeks.”
BackgroundMethodResultNeurobiological and genetic correlates of the dissociative subtype of posttraumatic stress disorder.
Wolf, E. J., Hawn, S. E., Sullivan, D. R., Miller, M. W., Sanborn, V., Brown, E., Neale, Z., Fein-Schaffer, D., Zhao, X., Logue, M. W., et al. (2023) · Journal of Psychopathology and Clinical Science · doi:10.1037/abn0000795 · Cited by 23
Averill, L. A., & Abdallah, C. G. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2035358 · Cited by 23
de Albuquerque, T. R., Macedo, L. F. R., Delmondes, G. D. A., Neto, M. L. R., Almeida, T. M., Uchida, R. R., Cordeiro, Q., Lisboa, K. W. D. S. C., & de Menezes, I. R. A. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221116477 · Cited by 29
“Other diseases that affect mental health, such as depression and anxiety, when associated with PTSD, favor a greater severity of symptoms.(2,3) PTSD can manifest acutely or chronically.”
BackgroundResultAlmeida, T. M., da Silva, U. R. L., Pires, J. P., Borges, I. N., Martins, C. R. M., Cordeiro, Q., & Uchida, R. R. (2024) · PubMed Central · doi:10.36131/cnfioritieditore20240102 · Cited by 51
“Among the ten studies included in our analysis, four (Feder et al., 2014; Feder et al., 2021; Abdallah et al., 2022; Harpaz-Rotem, 2022) assessed patients with moderate to severe PTSD based on their CAPS-5 scores.”
BackgroundInfluentialYang, S., Xu, K., Xu, X., Zhu, J., Jin, Y., Liu, Q., Xu, R. C., Gu, X., Liu, Y., Huang, Y., et al. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.848232 · Cited by 25
So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs
Borgogna, N. C., Owen, T., Vaughn, J., Johnson, D. A., Aita, S. L., & Hill, B. D. (2024) · European Journal of Psychotraumatology · doi:10.1080/20008066.2023.2299124 · Cited by 28
“In two of these studies (Abdallah et al., 2022; Feder et al., 2021), multiple ketamine administrations were employed, with one study examining low (0.2 mg/kg) and high (0.5 mg/kg) dosages (Abdallah et al., 2022).”
BackgroundMethodResultInfluentialHow Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
Doss, M. K., DeMarco, A., Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., & Nemeroff, C. B. (2024) · Drugs · doi:10.1007/s40265-024-02106-4 · Cited by 27
“…5-HT 2A -activating drugs, but note that hallucinogens such as dissociatives (i.e., NMDA receptor antagonists such as ketamine) and oneirogens (κ-opioid receptor agonists such as ibogaine) also show promise in treating PTSD [18, 19, 48–50] despite not sharing many of the mechanisms discussed here.”
Wolfgang, A. S., & Hoge, C. W. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01446-4 · Cited by 25
“MDMA-AT may entail 2–3 medication sessions, whereas protocols with other psychedelics may involve 1–2 medication sessions [49, 50].”
BackgroundKetamine for PTSD: Well, Isn’t That Special
Stein, M. B., & Simon, N. M. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20121677 · Cited by 19
Du, Z., Zang, Z., Luo, J., Liu, T., Yang, L., Cai, Y., Wang, L., Zhang, D., Zhao, J., Gao, J., et al. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.131379 · Cited by 20
Robison, R. J., Brendle, M., Moore, C., Cross, H., Helm, L., Darling, S., Thayer, S., Thielking, P. D., & Shannon, S. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2186285 · Cited by 25
“Recent evidence has shown ketamine’s efficacy in protecting against the detrimental effects of excessive stress while preventing a depressive response (Albott et al. 2018; Feder et al. 2014, 2020, 2021; Liriano, Hatten, and Schwartz 2019).”
BackgroundMaples‐Keller, J. L., Watkins, L. E., Hellman, N. M., Phillips, N. L., & ROTHBAUM, B. O. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.07.010 · Cited by 20
Ketamine treatment upon memory retrieval reduces fear memory in marmoset monkeys
Philippens, I. H. C. H. M., Draaisma, L. R., Baarends, G., Krugers, H. J., & Vermetten, E. H. G. J. M. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.04.004 · Cited by 18
“As recent studies are progressing in treatment of PTSD with ketamine ( Feder et al., 2021 , 2014 ), this study is needed to contribute to the potential of ketamine as a treatment for the emotional memory in PTSD ( Durand et al., 2019 ).”
Sippel, L. M., Hamblen, J. L., Kelmendi, B., Alpert, J. E., Carpenter, L. L., Grzenda, A. L., Kraguljac, N. V., McDonald, W. M., Rodríguez, C. I., Widge, A. S., et al. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230950 · Cited by 18
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review
Orsini, D. K., Wong, S., Luch, S. D. D., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0255 · Cited by 22
Is Prehospital Ketamine Associated With a Change in the Prognosis of PTSD?
Melcer, T., Walker, G. J., Dye, J. L., Walrath, B. D., MacGregor, A. J., Perez, K. G., & Galarneau, M. R. (2022) · Military Medicine · doi:10.1093/milmed/usac014 · Cited by 17
Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches
Bennett, R., Yavorsky, C., & BRAVO, G. L. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.867484 · Cited by 16
“Of special interest here is the potential overlap between bipolar spectrum disorders and complex post-traumatic stress disorder (CPTSD), which can look very similar upon initial presentation (13).”
BackgroundThe Emerging Role of Ketamine in Acute Postoperative Pain Management
Edinoff, A. N., Askins, D. H., Bobo, E., White, K. L., Eswani, Z., Jackson, E. D., Wenger, D. M., Kaye, A. J., Cornett, E. M., Kaye, A. M., et al. (2023) · Current Pain and Headache Reports · doi:10.1007/s11916-023-01134-1 · Cited by 20
Manipulating critical memory periods to treat psychiatry disorders
Deng, J., Lin, X., Zheng, Y., Su, S., Liu, X., Yuan, K., Shi, L., Bao, Y., & Lü, L. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.08.050 · Cited by 16
Driver, C., Jackson, T., Lagopoulos, J., & Hermens, D. F. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110609 · Cited by 18
Ketamine for Treatment of Posttraumatic Stress Disorder: State of the Field
Fremont, R., Brown, O., Feder, A., & Murrough, J. W. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20230006 · Cited by 18
Self-citationEntactogen Effects of Ketamine: A Reverse-Translational Study
Hess, E. M., Greenstein, D. K., Hutchinson, O. L., Zarate, C. A., & Gould, T. D. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230980 · Cited by 17
Psychoactive Drugs in the Management of Post Traumatic Stress Disorder: A Promising New Horizon
Elsouri, K. N., Kalhori, S., Colunge, D., Grabarczyk, G., Hanna, G., Carrasco, C., Espino, A. A., Francisco, A., Borosky, B., Bekheit, B., et al. (2022) · Cureus · doi:10.7759/cureus.25235 · Cited by 21
“Ketamine was approved by the FDA as an anesthetic agent in 1970 [47].”
BackgroundMethodGonda, X., Döme, P., Erdelyi-Hamza, B., Krause, S., Elek, L. P., Sharma, S., & Tarazi, F. I. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.05.010 · Cited by 15
Wang, S., Tang, S., Huang, J., & Chen, H. (2022) · General Psychiatry · doi:10.1136/gpsych-2022-100922 · Cited by 15
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
“…been found to improve PTSD symptom severity for up to 2 weeks (mean difference in Clinician-Administered PTSD Scale for DSM-5 [CAPS-5] scores relative to midazolam: 2 11.88 points, d 5 1.13, P 5 0.004), 162, p. 202 with 1 open-label trial reporting median relapse time in re-mitters to be 41 days.”
BackgroundInfluentialRamakrishnan, N., Lijffijt, M., Green, C. E., Balderston, N. L., Murphy, N., Grillon, C., Iqbal, T., Vo‐Le, B., O’Brien, B., Murrough, J. W., et al. (2021) · Depression and Anxiety · doi:10.1002/da.23194 · Cited by 12
“…studies with the NMDAR antagonist ketamine have reported rapid benefit for varied conditions associated with elevated arousal and anxious reactivity, including PTSD (Albott et al., 2018; Feder et al., 2014; 2021) depression, (Murrough et al., 2013; Newport et al., 2015) and suicidal ideation.”
BackgroundResultSelf-citationShiroma, P. R., Velit-Salazar, M. R., & Vorobyov, Y. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01169-z · Cited by 12
“The improvement in severity of depression [3] and PTSD [41] symptoms after ketamine could be in part related to normalization of executive functions, such as working memory and shifting, as well as emotion regulation (Fig.”
BackgroundArgento, E., Omene, E., Jaeger, A. H., Kertes, A., Mitchell, K. A., Necyk, C., Thielking, P. D., & Lewis, E. C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1197409 · Cited by 12
“While less robust than the research on depression, a growing body of evidence, including from randomized clinical trials, lends support to utilizing ketamine in the treatment of PTSD, particularly given that effective pharmacological treatments for PTSD are limited (Albott et al., 2018; Feder et al., 2021).”
BackgroundGao, B., Qu, Y.-C., Cai, M., Zhang, Y.-Y., Lu, H., Li, H.-X., Tang, Y., & Shen, H. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.06.006 · Cited by 12
Ryan, K., & Hosanagar, A. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01432-w · Cited by 11
Through a Developmental Lens: Emerging Insights to Understand and Treat Pediatric PTSD
Russell, J. D., Heyn, S. A., & Herringa, R. J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230523 · Cited by 12
“Emerging studies in adults also suggest a potential benefit of neuroplastic agents such as ketamine and MDMA in adult PTSD (115, 116).”
BackgroundHovda, N., Gerrish, W. G., Frizzell, W., & Shackelford, R. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.120 · Cited by 15
Moore, T. M., Walker, K. C., Tung, E., Teed, A. R., Hell, F., Kinreich, S., Jung, R., Abdel, F., Hanson, R. W., & Ahmed, S. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.041 · Cited by 15
Yu, W., Wu, Z., Li, X., Ding, M., Xu, Y., & Zhao, P. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03474-w · Cited by 11
Norred, M. A., Zuschlag, Z. D., & Hamner, M. B. (2024) · Drugs · doi:10.1007/s40265-023-01983-5 · Cited by 17
“Early studies have suggested potential efficacy for ketamine in PTSD, both with a single infusion [72] and with multiple infusions over the course of 2 weeks [73].”
Shiroma, P. R., THURAS, P. D., Polusny, M. A., Kehle‐Forbes, S., Disner, S. G., Pardo, J. V., Gilmore, C. S., Tolly, B., Voller, E. K., McManus, E. S., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107569 · Cited by 11
Ziobrowski, H. N., Holt-Gosselin, B., Petukhova, M. V., King, A. J., Lee, S., House, S. L., Beaudoin, F. L., An, X., Stevens, J. S., Zeng, D., et al. (2023) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796022000798 · Cited by 12
“To address these limitations of previous research, we analysed data from a large prospective study of adults presenting at EDs following motor vehicle collision (MVC) to determine whether patient-reported CA history predicted APNS three months later, the amount of time traditionally used to define chronic PTSD (Feder…”
MethodInfluentialSelf-citationDeng, Q., Parker, E., Wu, C., Zhu, L., Liu, T. C., Duan, R., & Yang, L. (2024) · Aging and Disease · doi:10.14336/ad.2024.0239 · Cited by 12
“Multiple investigations have shown that repeated ketamine leads to rapid and sustained improvement in depressive symptoms and PTSD, with the therapy deemed safe for repeated use [8, 257-259].”
Guo, P., Yu, F., Feng, M., Zhao, X., Wang, S., Qian, M., Huang, J., & Chen, H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.803220 · Cited by 12
“More than half of patients with PTSD do not achieve remission after treatments with antidepressants and psychotherapy (6), or after repeated applications of the rapid antidepressant, ketamine (7, 8).”
BackgroundProposing Bromo-Epi-Androsterone (BEA) for Post-Traumatic Stress Disorder (PTSD)
Dow, C. T., & Obaid, L. (2025) · Cells · doi:10.3390/cells14141120 · Cited by 12
“Glutamatergic drugs are emerging as powerful (e.g., ketamine for rapid symptom control) [84], D-cycloserine to enhance therapy [85]), highlighting the role of learning and extinction pathways in recovery.”
Danböck, S. K., Duek, O. A., Ben‐Zion, Z., Korem, N., Amen, S. L., Kelmendi, B., Wilhelm, F. H., Levy, I., & Harpaz‐Rotem, I. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06479-4 · Cited by 10
“The present study focuses on ketamine administered at 0.5mg/kg over 40 min, a subanes-thetic dose and infusion time frequently studied in individuals with psychiatric disorders (Feder et al. 2014, 2021; Short et al. 2018; Duek et al. 2019; Dehestani et al. 2022; Abdallah et al. 2022).”
InfluentialThe metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
(2023) · International Review of Neurobiology · doi:10.1016/bs.irn.2022.10.007 · Cited by 8
Enhancing Fear Extinction: Pharmacological Approaches
Ponomareva, O. Y., Fenster, R. J., & Ressler, K. J. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_443 · Cited by 8
Ketamine-assisted buprenorphine initiation: a pilot case series
Grande, L. A., Hutch, T., Jack, K., Mironov, W., Iwuoha, J., Muy-Rivera, M., Grillo, J., Martin, S. A., & Herring, A. A. (2024) · Addiction Science & Clinical Practice · doi:10.1186/s13722-024-00494-2 · Cited by 9
“Early pre-clinical and clinical research has shown potential for the treatment of anxiety [15], post-traumatic stress disorder [16], and substance use disorder [17].”
BackgroundMikellides, G. (2025) · Psychoactives · doi:10.3390/psychoactives4030020 · Cited by 9
“These benefits are thought to be mediated, in part, by ketamine’s effects on memory reconsolidation and synaptic plasticity, offering a novel mechanism distinct from traditional pharmacotherapy [16].”
Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review
Kerr‐Gaffney, J., Tröger, A., Caulfield, A., Ritter, P. S., Rucker, J., & Young, A. H. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251350267 · Cited by 9
“The second study administered 6 infusions of ketamine or midazolam over 2 weeks (Feder et al., 2021).”
Metadata
- Authors
- Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Bevilacqua, L., Glasgow, A. M., Brallier, J., Pietrzak, R. H., Murrough, J. W., & Charney, D. S.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2021-02-01
- Volume
- 178
- Issue
- 2
- Pages
- 193-202
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3120445729
- Cited by
- 246
- References
- 37
- Citations by year
- 2026: 43 · 2025: 43 · 2024: 41 · 2023: 50 · 2022: 47 · 2021: 22
- FWCI
- 27.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- post-traumatic stress disorder, chronic PTSD, ketamine, treatment response durability, depression, adverse effects, pharmacotherapy
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Chronic Disease, Depression, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Stress Disorders, Post-Traumatic, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.